EBIT: Income before interest and taxes.
AN2 Therapeutics, Inc. (ANTX) had EBIT of $-11.54M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-10.65M |
|
-- |
|
-- |
|
$11.54M |
|
$-11.54M |
|
$0.89M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
|
EBIT |
$-11.54M |
$-11.98M |
|
30.05M |
|
30.05M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$69.56M |
|
-- |
|
$11.78M |
|
$81.34M |
|
$8.01M |
|
-- |
|
-- |
|
$8.01M |
|
$73.33M |
|
$73.33M |
|
$73.33M |
|
30.14M |
|
| Cash Flow Statement Financials | |
$-10.62M |
|
$9.19M |
|
$0.07M |
|
$21.35M |
|
$19.98M |
|
$-1.37M |
|
$2.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.68 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.62M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.52% |
|
-14.52% |
|
-13.09% |
|
-14.52% |
|
$2.43 |
|
$-0.35 |
|
$-0.35 |
|